Prelude Therapeutics Incorporated – NASDAQ:PRLD

Add to watchlist

$0.851

-0.48

-36.48%

Market closed

Open in 2 days

-70.61%

month

-70.61%

quarter

-66.75%

year

Market Cap	77.04M
Enterprise value	332.19M

P/E	-3.34
EV/Sales	N/A
EV/EBITDA	-1.98
Price/Sales	N/A
Price/Book	1.84
PEG ratio	8.11
EPS	-1.89

Revenue	N/A
EBITDA	-136.89M
Income	-125.54M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Prelude Therapeutics Incorporated (NASDAQ:PRLD): Profit margin
Jun 2023	0	-30.43M
Sep 2023	0	-30.60M
Dec 2023	3.42M	-33.07M	-965.98%
Mar 2024	0	-31.43M

Prelude Therapeutics Incorporated Financials Estimate

Q Y

Prelude Therapeutics Incorporated (NASDAQ:PRLD): Analyst Estimates
Mar 2024	0	-31.43M
Sep 2025	0	-28.00M
Oct 2025	0	-27.26M
Dec 2025	0	-27.26M

Analysts Price target
Financials & Ratios estimates

Prelude Therapeutics Incorporated (NASDAQ:PRLD): Debt to assets
Jun 2023	280611000	18.55M	6.61%
Sep 2023	258511000	20.25M	7.83%
Dec 2023	277665000	40.57M	14.61%
Mar 2024	247106000	36.37M	14.72%

Prelude Therapeutics Incorporated (NASDAQ:PRLD): Cash Flow
Jun 2023	-27.66M	-75.42M	111.33M
Sep 2023	-25.68M	15.04M	88K
Dec 2023	-23.57M	7.73M	25.23M
Mar 2024	-31.79M	31.22M	-14K

Prelude Therapeutics Incorporated alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Prelude Therapeutics Incorporated
Employees

Prelude Therapeutics Incorporated (NASDAQ:PRLD): Employee count
Aug 2023	122
Sep 2023	122
Oct 2023	122
Nov 2023	122
Dec 2023	122
Jan 2024	122
Feb 2024	122
Mar 2024	128
Apr 2024	128
May 2024	128
Jun 2024	128
Jul 2024	128

Prelude Therapeutics Incorporated
Hedge Funds Holdings Q1 2023

12.66% -53.05%

of PRLD is owned by hedge funds

26 -34

hedge funds hold PRLD stock

5.99M -25.18M

shares is hold by hedge funds

PRLD hedge funds holdings changes

Prelude Therapeutics Incorporated
Insider Trading

Prelude Therapeutics Incorporated (NASDAQ:PRLD): Insider trades (number of shares)
Period	Buy	Sel
Dec 2024	194963	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	23 Dec 2024	COMBS ANDREW officer: Chief Chemistry Officer officer: Chief Chemistry Officer	Common Stock	60,000	$1.37	$82,020
Purchase	20 Dec 2024	COMBS ANDREW officer: Chief Chemistry Officer officer: Chief Chemistry Officer	Common Stock	3,075	$1.15	$3,536
Purchase	19 Dec 2024	LIM BRYANT DAVID officer: CLO, Int..	Common Stock	25,000	$0.91	$22,650
Purchase	19 Dec 2024	VADDI KRISHNA director, officer: CEO director, officer: CEO	Common Stock	6,888	$0.89	$6,117
Purchase	18 Dec 2024	VADDI KRISHNA director, officer: CEO director, officer: CEO	Common Stock	100,000	$0.93	$93,200
Option	4 Jul 2024	HUANG JANE officer: President, CMO officer: President, CMO	Restricted Stock Unit	9,375	N/A	N/A
Option	4 Jul 2024	HUANG JANE officer: President, CMO officer: President, CMO	Common Stock	9,375	N/A	N/A
Option	4 Apr 2024	HUANG JANE officer: President, CMO officer: President, CMO	Restricted Stock Unit	9,375	N/A	N/A
Option	4 Apr 2024	HUANG JANE officer: President, CMO officer: President, CMO	Common Stock	9,375	N/A	N/A
Option	4 Jan 2024	HUANG JANE officer: President, CMO officer: President, CMO	Restricted Stock Unit	9,375	N/A	N/A

PRLD insider trading transactions

Prelude Therapeutics Incorporated
Patents

Status	Patent	Filling date	Issue date
Application	Application Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) Filling date: 3 Apr 2020 Issue date: 14 Jul 2022	3 Apr 2020	14 Jul 2022
Application	Application SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) Filling date: 17 Feb 2022 Issue date: 9 Jun 2022	17 Feb 2022	9 Jun 2022
Application	Application SELECTIVE INHIBITOR OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) Filling date: 13 Feb 2020 Issue date: 26 May 2022	13 Feb 2020	26 May 2022
Application	Application Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) Filling date: 18 Nov 2021 Issue date: 19 May 2022	18 Nov 2021	19 May 2022
Application	Application Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) Filling date: 3 Apr 2020 Issue date: 19 May 2022	3 Apr 2020	19 May 2022
Application	Application CDK Inhibitors And Their Use As Pharmaceuticals Filling date: 21 Sep 2021 Issue date: 24 Mar 2022	21 Sep 2021	24 Mar 2022
Application	Application BICYCLIC HETEROCYCLIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS Filling date: 13 Dec 2019 Issue date: 3 Mar 2022	13 Dec 2019	3 Mar 2022
Grant	Grant Utility: Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) Filling date: 5 Aug 2020 Issue date: 22 Feb 2022	5 Aug 2020	22 Feb 2022
Application	Application BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Filling date: 9 Jun 2021 Issue date: 3 Feb 2022	9 Jun 2021	3 Feb 2022
Grant	Grant Utility: Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) Filling date: 20 Feb 2018 Issue date: 11 Jan 2022	20 Feb 2018	11 Jan 2022

PRLD patents

Prelude Therapeutics Incorporated
Executives

Insider	Age	Since	Compensation
Dr. Krishna Vaddi D.V.M., Ph.D. (1966) Founder, Chief Executive Officer & Director	59		$645,730
Dr. Deborah Morosini (1959) Executive Vice President & Chief of Clinical Affairs	66		$326,810

Prelude Therapeutics Incorporated
Latest News

Wednesday, 11 December 2024
07:30	Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies	globenewswire.com
Wednesday, 27 November 2024
10:36	After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD)	zacks.com
07:30	Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit	globenewswire.com
Monday, 11 November 2024
10:35	Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD)	zacks.com
Thursday, 24 October 2024
07:30	Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium	globenewswire.com
Wednesday, 9 October 2024
07:30	Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium	globenewswire.com
Friday, 13 September 2024
10:00	Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial	globenewswire.com
Monday, 9 September 2024
07:30	Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024	globenewswire.com
Tuesday, 9 July 2024
07:30	Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers	globenewswire.com
Monday, 3 June 2024
07:01	Prelude Therapeutics to Participate in Upcoming Healthcare Conferences	globenewswire.com
Thursday, 9 May 2024
07:01	Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference	globenewswire.com
Tuesday, 7 May 2024
07:01	Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	globenewswire.com
Tuesday, 9 April 2024
16:35	Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting	globenewswire.com
Tuesday, 5 March 2024
16:45	Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting	globenewswire.com
Thursday, 29 February 2024
16:05	Prelude Therapeutics to Participate in Barclays Global Healthcare Conference	GlobeNewsWire
Thursday, 25 January 2024
07:41	New Strong Buy Stocks for January 25th	Zacks Investment Research
Wednesday, 4 October 2023
13:31	All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy	Zacks Investment Research
Thursday, 27 April 2023
08:30	Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May	GlobeNewsWire
Tuesday, 11 April 2023
08:30	Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference	GlobeNewsWire
Saturday, 18 March 2023
18:48	The 7 Worst Stocks to Buy Now	InvestorPlace
Thursday, 16 March 2023
13:46	Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate	Zacks Investment Research
Thursday, 9 February 2023
09:05	Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences	GlobeNewsWire
Wednesday, 10 August 2022
10:32	Is a Surprise Coming for Prelude Therapeutics (PRLD) This Earnings Season?	Zacks Investment Research
Wednesday, 22 June 2022
11:35	Wall Street Analysts Predict a 169% Upside in Prelude Therapeutics Incorporated (PRLD): Here's What You Should Know	Zacks Investment Research
Friday, 11 March 2022
08:00	Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference	GlobeNewsWire
Friday, 11 February 2022
07:00	Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference	GlobeNewsWire
Tuesday, 4 January 2022
07:00	Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference	GlobeNewsWire
Friday, 17 December 2021
13:50	The 10 Most Shorted Stocks Right Now for Friday, Dec. 17	InvestorPlace
Thursday, 7 October 2021
09:00	Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of Prelude Therapeutics Incorporated stock today?

One share of Prelude Therapeutics Incorporated stock can currently be purchased for approximately $0.85.
When is Prelude Therapeutics Incorporated's next earnings date?

Unfortunately, Prelude Therapeutics Incorporated's (PRLD) next earnings date is currently unknown.
Does Prelude Therapeutics Incorporated pay dividends?

No, Prelude Therapeutics Incorporated does not pay dividends.
How much money does Prelude Therapeutics Incorporated make?

Prelude Therapeutics Incorporated has a market capitalization of 77.04M.
What is Prelude Therapeutics Incorporated's stock symbol?

Prelude Therapeutics Incorporated is traded on the NASDAQ under the ticker symbol "PRLD".
What is Prelude Therapeutics Incorporated's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Prelude Therapeutics Incorporated?

Shares of Prelude Therapeutics Incorporated can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Prelude Therapeutics Incorporated's key executives?
Prelude Therapeutics Incorporated's management team includes the following people:
- Dr. Krishna Vaddi D.V.M., Ph.D. Founder, Chief Executive Officer & Director(age: 59, pay: $645,730)
- Dr. Deborah Morosini Executive Vice President & Chief of Clinical Affairs(age: 66, pay: $326,810)
Is Prelude Therapeutics Incorporated founder-led company?

Yes, Prelude Therapeutics Incorporated is a company led by its founder Dr. Krishna Vaddi D.V.M., Ph.D..
How many employees does Prelude Therapeutics Incorporated have?

As Jul 2024, Prelude Therapeutics Incorporated employs 128 workers.
When Prelude Therapeutics Incorporated went public?

Prelude Therapeutics Incorporated is publicly traded company for more then 4 years since IPO on 25 Sep 2020.
What is Prelude Therapeutics Incorporated's official website?

The official website for Prelude Therapeutics Incorporated is preludetx.com.
Where are Prelude Therapeutics Incorporated's headquarters?

Prelude Therapeutics Incorporated is headquartered at 200 Powder Mill Road, Wilmington, DE.
How can i contact Prelude Therapeutics Incorporated?

Prelude Therapeutics Incorporated's mailing address is 200 Powder Mill Road, Wilmington, DE and company can be reached via phone at +30 24671280.

Prelude Therapeutics Incorporated

preludetx.com

Exchange:

NASDAQ

Full time employees:

128

Industry:

Biotechnology

Sector:

Healthcare

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

+30 24671280

200 Powder Mill Road
Wilmington, DE 19803

CIK: 0001678660
ISIN: US74065P1012
CUSIP: 74065P101